NIKKEI 225
29,199.22 +330.31 (+1.14%) HANG SENG
19,982.74 +152.22 (+0.77%) CRUDE OIL
87.51 +0.98 (+1.13%) GOLD FUTURES
1,795.30 +5.60 (+0.31%) DOW
34,152.01 +239.61 (+0.71%) BTC-GBP
19,906.80 +64.18 (+0.32%)
AERI Aug 2022 15.000 put
| Previous close | 7.30 |
| Open | 7.30 |
| Bid | 7.50 |
| Ask | 8.40 |
| Strike | 15.00 |
| Expiry date | 2022-08-19 |
| Day's range | 7.30 - 7.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
- Zacks
Roche's (RHHBY) sBLA For Polivy Combo Accepted by FDA
Roche's (RHHBY) sBLA seeking approval for the use of Polivy in combination with R-CHP for previously untreated diffuse large B-cell lymphoma in adults has been accepted in the United States.
- Business Wire
Aerie Pharmaceuticals Announces New Employee Inducement Grant
DURHAM, N.C., August 15, 2022--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced that the compensation committee of Aerie Pharmaceutical’s board of directors granted one new employee an award totaling 16,900 stock options that will vest over 4 years, with 25% vesti
- Zacks
Wall Street Analysts See a 75% Upside in Aerie (AERI): Can the Stock Really Move This High?
The consensus price target hints at a 75.1% upside potential for Aerie (AERI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
